Gut Feelings Psychiatry Expands Treatment Options to Include Psychedelics for Depression

Gut Feelings Psychiatry has announced the inclusion of psychedelics in its treatment options, specifically targeting individuals suffering from severe or treatment-resistant depression. This innovative approach utilizes ketamine in various forms—intramuscular, intravenous, and intranasal—to offer rapid relief from depression symptoms. Although ketamine's use for depression is considered off-label, the clinic is an approved Risk Evaluation and Mitigation Strategy (REMS) site for intranasal esketamine, known as Spravato, which has FDA approval and may be covered by insurance.

The decision to incorporate psychedelics into their treatment repertoire underscores Gut Feelings Psychiatry's commitment to a holistic approach to mental health and wellness. Beyond psychedelic treatments, the clinic provides a range of services including medication management, weight loss programs, and specialized care for chronic gut health issues. Additionally, Gut Feelings Psychiatry extends its expertise to the business sector through startup advising and public speaking engagements.

This expansion into psychedelic treatments represents a pivotal moment in mental health care, offering new hope for patients who have not found relief through traditional methods. With services available virtually across several states and in-person consultations in select California cities, Gut Feelings Psychiatry is poised to make a significant impact on the accessibility and effectiveness of mental health treatments. For more information, visit https://www.mygutfeelings.com.